Organisation paid for research Program year 2025 Source: CMS Open Payments

Tidewater Physicians Multispecialty Group

Neither a doctor nor a teaching hospital

Research payments

$363,584

1,070 payments

Through program year 2025, Tidewater Physicians Multispecialty Group is reported as receiving $363,584 in research payments, across 1,070 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$94,371	5
2024	Research	$69,124	16
2023	Research	$32,958	2
2021	Research	$128,270	1,015
2020	Research	$20,891	18
2019	Research	$17,970	14

Breakdown

Who paid Research payments · program years 2019–2025

Medtronic, Inc. $139,106 11 payments
Novo Nordisk AS $103,668 1,014 payments
GlaxoSmithKline, LLC. $35,792 21 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $26,024 2 payments
Celgene Corporation $21,000 1 payment
AbbVie, Inc. $14,081 11 payments
AstraZeneca Pharmaceuticals LP $11,958 1 payment
Boehringer Ingelheim International GmbH $9,321 5 payments
Janssen Research & Development, LLC $2,632 4 payments

Studies the money was for Research payments · program years 2019–2025

Enable - Hernia $95,770 4 payments
Nn1436-4477 $60,771 480 payments
Recover $43,336 7 payments
Nn1436-4481 $37,897 533 payments
Empagliflozin for prevention of HHF and death after an AMI $35,346 7 payments
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Para $22,889 9 payments
Ph III Yellowstone CD Maintenance (RPC01-3203) - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn s Disease $21,000 1 payment
M16-063 $14,081 11 payments
A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease $11,958 1 payment
A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro $7,732 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.